Natco Pharma is currently trading at Rs. 943.80, up by 2.15 points or 0.23% from its previous closing of Rs. 941.65 on the BSE.
The scrip opened at Rs. 954.70 and has touched a high and low of Rs. 954.70 and Rs. 918.60 respectively. So far 5595 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 995.05 on 28-Sep-2020 and a 52 week low of Rs. 450.00 on 25-Mar-2020.
Last one week high and low of the scrip stood at Rs. 967.05 and Rs. 918.60 respectively. The current market cap of the company is Rs. 17194.75 crore.
The promoters holding in the company stood at 48.91%, while Institutions and Non-Institutions held 33.03% and 18.07% respectively.
Natco Pharma has launched Rivaroxaban molecule, under brand RPIGAT. Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots. Rivaroxaban is currently sold by Bayer under brand name of Xarelto, in the Indian market.
After successful previous launches of DABIGAT (Dabigatran) and APIGAT (Apixaban) by NATCO, this latest Rivaroxaban NOAC (Novel oral anti-coagulant) is in line with Company's mission of affordable medicines accessible to all. NATCO has launched RPIGAT in four strengths- 20 mg, 15 mg, 10 mg and 2.5 mg. The 20 mg strength is priced at an MRP of Rs 14.0 per tablet.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
